Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236726 | 1.00 | TSHR (0.58) | TSHRLMNAMAPK1CACNA2D1CACNB2 | |
| SCHEMBL235417 | 1.00 | TSHR (0.58) | TSHRLMNAMAPK1CACNA2D1CACNB2 | |
| Carbamic Acid SCHEMBL10434705 | 0.89 | TSHR (0.48) | TSHRLMNAMAPK1CYP2D6SRC | |
| Acetic Acid SCHEMBL28643353 | 0.89 | TSHR (0.48) | TSHRLMNAMAPK1CACNA2D1CACNB2 | |
| SCHEMBL6390318 | 0.86 | PTGS2 (0.48) | TSHRALDH1A1CYP2D6 | |
| SCHEMBL29184903 | 0.86 | ESR1 (0.46) | TSHR | |
| SCHEMBL8681266 | 0.81 | TSHR (0.41) | TSHRLMNAMAPK1ALDH1A1HIF1A | |
| SCHEMBL6965069 | 0.81 | SRD5A2 (0.54) | TSHR | |
| SCHEMBL9547891 | 0.78 | TSHR (0.64) | TSHRLMNAMAPK1CACNA2D1CACNB2 | |
| SCHEMBL6962580 | 0.77 | ESR1 (0.62) | TSHRLMNAALDH1A1KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 896 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036799-A | Gold (I) complex containing alkyne-based ligand, preparation method thereof and application thereof in preparation of antitumor drugs | 西南医科大学附属医院 | 2026-05-15 | — | — | CN | claimed |
| US-12559655-B2 | Polysiloxane-containing temporary adhesive comprising heat-resistant polymerization inhibitor | NISSAN CHEMICAL CORPORATION (JP) | 2026-02-24 | — | — | US | claimed |
| WO-2025053791-A1 | ONE-POT GRAFTING OF POLYMERS FROM ALCOHOLS AND BIOMASSES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| EP-4003710-B1 | A PROCESS FOR PRODUCING A MOLDED SILICONE RUBBER PRODUCT FROM LIQUID SILICONE RUBBER COMPOSITION VIA INJECTION MOLDING | ELKEM SILICONES USA CORP (US) | 2025-03-12 | — | — | EP | claimed |
| US-20240368402-A1 | HYDROSILYLATION CURE INHIBITORS AND USE THEREOF | DOW SILICONES CORP (US) | 2024-11-07 | — | — | US | claimed |
| US-12071543-B2 | Hydrosilylation cure inhibitors and use thereof | DOW SILICONES CORPORATION (US) | 2024-08-27 | — | — | US | claimed |
| EP-4251402-B1 | HYDROSILYLATION CURE INHIBITORS AND USE THEREOF | DOW SILICONES CORP (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118108718-A | Benzimidazolo [1,2-b ] isoquinoline compounds, and preparation and application thereof | 中国科学院大连化学物理研究所 | 2024-05-31 | — | — | CN | claimed |
| CN-116406323-B | Hydrosilylation cure inhibitors and uses thereof | 美国陶氏有机硅公司 | 2024-04-02 | — | — | CN | claimed |
| US-11905413-B2 | Process and a device assembly useful for producing a molded silicone rubber product from liquid silicone rubber composition via injection molding | Elkem Silicones USA Corp. (US) | 2024-02-20 | — | — | US | claimed |
| US-5801183-A | HETEROCYCLC ALCOHOLS FOR NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1998-09-01 | — | — | US | claimed |
| WO-1997031044-A1 | WATER-DISPERSIBLE POLYMER AND COATING COMPOSITION CONTAINING THE SAME | THE DEXTER CORPORATION (US) | 1997-08-28 | — | — | WO | claimed |
| EP-0476645-B1 | Calcium uptake inhibitors | MERRELL DOW PHARMA (US) | 1995-09-06 | — | — | EP | claimed |
| EP-0404030-B1 | Method for coating substrates with UV curable epoxysilicone compositions | GEN ELECTRIC (US) | 1994-02-09 | — | — | EP | claimed |
| EP-0476645-A1 | Calcium uptake inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-25 | — | — | EP | claimed |
| EP-0192130-B1 | CORROSION INHIBITOR COMPOSITION | HENKEL CORPORATION (a Delaware corp.) (US) | 1990-06-27 | — | — | EP | claimed |
| EP-0324191-A1 | Tert.-butyl alkynols | BASF Aktiengesellschaft (DE) | 1989-07-19 | — | — | EP | claimed |
| EP-0192130-A2 | Corrosion inhibitor composition | HENKEL CORPORATION (a Delaware corp.) (US) | 1986-08-27 | — | — | EP | claimed |
| EP-0169400-A1 | Aminomethyl derivatives and preparation process thereof as well as platelet aggregation inhibitors containing same | SS PHARMACEUTICAL CO., LTD. (JP) | 1986-01-29 | — | — | EP | claimed |
| US-3994936-A | Catalytic rearrangement | HOFFMANN-LA ROCHE INC. (US) | 1976-11-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559655-B2 | Polysiloxane-containing temporary adhesive comprising heat-resistant polymerization inhibitor | ITGA1, HSPA1A, TCP1 | TSHR 1618/4885LMNA 1297/4885MAPK1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.